HLA-C and neoplasm: US6149905A (“Tumor cells with increased immunogenicity and uses therefor”) [25], US201001195 37A1 (“Tumor Vaccine”) [26], and US7807186B2 (“Tumor cells from immune-privileged sites as base cells for cell-based cancer vaccines” [27]) go a step further than EP0569678A2 [23] and US5750102A [24] in that they focus on B7 co-stimulatory molecules and claim those in combination with MHC molecules.